Eagle Bay Advisors’s Fate Therapeutics FATE Stock Holding History

Eagle Bay Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-76	Closed	-$125	–	409
2024 Q4	$125	Hold	76	–	–	﹤0.01%	985
2024 Q3	$266	Hold	76	–	–	﹤0.01%	1325
2024 Q2	$249	Hold	76	–	–	﹤0.01%	967
2024 Q1	$558	Hold	76	–	–	﹤0.01%	941
2023 Q4	$284	Hold	76	–	–	﹤0.01%	812
2023 Q3	$161	Hold	76	–	–	﹤0.01%	834
2023 Q2	$362	Hold	76	–	–	﹤0.01%	818
2023 Q1	$433	Hold	76	–	–	﹤0.01%	876
2022 Q4	$767	Hold	76	–	–	﹤0.01%	849
2022 Q3	$2K	Hold	76	–	–	﹤0.01%	759
2022 Q2	$1.88K	Buy	+76	New	+$2.1K	﹤0.01%	827
2022 Q1	–	Sell	-76	Closed	-$4K	–	530
2021 Q4	$4K	Hold	76	–	–	﹤0.01%	828
2021 Q3	$5K	Buy	+76	New	+$5.96K	﹤0.01%	828

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Eagle Bay Advisors's FATE Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 76 shares — an estimated $125 sold.

Eagle Bay Advisors first reported a position in FATE in Q3 2021 and held it in 13 quarters. The position peaked at $5K in Q3 2021. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

Eagle Bay Advisors reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 76 Fate Therapeutics shares in Q1 2025, an estimated $125.
Eagle Bay Advisors first reported a position in Fate Therapeutics in Q3 2021 and held it in 13 quarters.
Eagle Bay Advisors's Fate Therapeutics position peaked at $5K in Q3 2021.
132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.